Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Navigating Pregnancy Safety and Systemic Treatments in Atopic Dermatitis : Episode 1

Opinion

Video

June 12, 2024

Unveiling Treatment Gaps: Expert Perspectives on the Undermanagement of Patients with Atopic Dermatitis and Childbearing Potential

Author(s):

Elizabeth Kiracofe, MD, FAAD,Jenny Murase, MD, FAAD

Dr. Elizabeth Kiracofe, MD, FAAD, and Dr. Jenny Murase, MD, introduce a discussion on the undertreatment of patients with atopic dermatitis, particularly focusing on pregnant individuals and those of childbearing age.

Now Viewing

EP: 1.Unveiling Treatment Gaps: Expert Perspectives on the Undermanagement of Patients with Atopic Dermatitis and Childbearing Potential

EP: 2.Fostering Communication: Promoting Dialogue on Atopic Dermatitis Treatment Concerns in Patients of Childbearing Potential

EP: 3.Exploring Changes in Atopic Dermatitis Severity Across the Pregnancy Journey

EP: 4.Navigating Treatment Choices: Balancing Treatment Options for Childbearing-Age Patients

EP: 5.Insights on Transcription Binding in Atopic Dermatitis

EP: 6.Informed Decisions: Dialogue with Treatment-Naïve Pregnant Patients Regarding Systemic Atopic Dermatitis Treatment Options

EP: 7.Managing Atopic Dermatitis Treatment Escalation in Pregnancy: Considerations and Approaches

EP: 8.Urgent Need for Consensus on Systemic Treatments for Atopic Dermatitis in Childbearing-Age Populations

EP: 9.Considerations for Breastfeeding, Lactation, and Postpartum in Family Planning Patients with Atopic Dermatitis

EP: 10.Concluding Remarks: Systemic Treatment Considerations for Atopic Dermatitis in Patients of Childbearing Potential

EP: 11.Ten Clinical Considerations to Manage AD in Pregnant Patients

Video content above is prompted by the following question(s):

Please comment on the issue of undertreatment and underdosing in pregnant populations, even when data supports their potential efficacy and safety.
How might this bias hinder optimizing care and the willingness to use potentially higher-risk but more efficacious systemic therapies?